MedTrace Logo

Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney Disease

NCT01598740 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2013-07-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effects of CLP, with and without spironolactone, on serum, urine, and fecal contents in heart failure patients with chronic kidney disease.

Conditions

Interventions

DRUG

CLP

Oral administration

DRUG

Spironolactone

oral administration

Sponsors & Collaborators

  • Sorbent Therapeutics

    lead INDUSTRY

Principal Investigators

  • Howard Dittrich, MD · Sorbent Therapeutics, Study Sponsor

  • Joel Neutel, MD · Orange County Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01598740 on ClinicalTrials.gov